PL365779A1 - A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes - Google Patents

A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes

Info

Publication number
PL365779A1
PL365779A1 PL01365779A PL36577901A PL365779A1 PL 365779 A1 PL365779 A1 PL 365779A1 PL 01365779 A PL01365779 A PL 01365779A PL 36577901 A PL36577901 A PL 36577901A PL 365779 A1 PL365779 A1 PL 365779A1
Authority
PL
Poland
Prior art keywords
diabetes
treatment
combination
agents useful
antidiabetic agents
Prior art date
Application number
PL01365779A
Other languages
English (en)
Polish (pl)
Inventor
Poelje Paul D. Van
Mark D. Erion
Toshihiko Fujiwara
Original Assignee
Metabasis Therapeutics, Inc.
Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics, Inc., Sankyo Company, Limited filed Critical Metabasis Therapeutics, Inc.
Publication of PL365779A1 publication Critical patent/PL365779A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL01365779A 2000-07-06 2001-07-05 A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes PL365779A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21653100P 2000-07-06 2000-07-06

Publications (1)

Publication Number Publication Date
PL365779A1 true PL365779A1 (en) 2005-01-10

Family

ID=22807416

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01365779A PL365779A1 (en) 2000-07-06 2001-07-05 A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes

Country Status (18)

Country Link
EP (1) EP1372660A2 (fr)
JP (1) JP2004508297A (fr)
KR (1) KR100854851B1 (fr)
CN (2) CN100396283C (fr)
AU (2) AU7327101A (fr)
BR (1) BR0112212A (fr)
CA (1) CA2412142A1 (fr)
CZ (1) CZ20035A3 (fr)
HU (1) HUP0301830A3 (fr)
IL (2) IL153513A0 (fr)
MX (1) MXPA02012713A (fr)
NO (1) NO20030034L (fr)
NZ (1) NZ523227A (fr)
PL (1) PL365779A1 (fr)
RU (1) RU2328308C2 (fr)
SK (1) SK62003A3 (fr)
WO (1) WO2002003978A2 (fr)
ZA (1) ZA200300044B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039344A1 (fr) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Nouveaux composes de purine inhibiteurs de fructose-1,6-biophasphatase
DK1112275T3 (da) 1998-09-09 2003-11-24 Metabasis Therapeutics Inc Hidtil ukendte heteroaromatiske inhibitorer for fructose-1,6-bisphosphatase
IL151248A0 (en) 2000-03-08 2003-04-10 Metabasis Therapeutics Inc Novel aryl fructose-1,6-bisphosphatase inhibitors
IL160983A0 (en) 2001-09-24 2004-08-31 Imp College Innovations Ltd Use of pyy for preparation of a medicament for modification of feeding behavior
AU2003201998C1 (en) 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
CN1902196B (zh) 2003-12-26 2010-12-29 协和发酵麒麟株式会社 噻唑衍生物
BRPI0514372A (pt) * 2004-08-18 2008-06-10 Metabasis Therapeutics Inc inibidores de tiazol de frutose 1, 6-bisfosfatase
TW200633720A (en) * 2004-12-13 2006-10-01 Sankyo Co Medicinal composition for diabetic
TW200738245A (en) * 2005-08-22 2007-10-16 Sankyo Co Pharmaceutical composition containing FBPase inhibitor
WO2007129522A1 (fr) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited Préparation obtenue par voie sèche
WO2008063842A2 (fr) 2006-11-02 2008-05-29 Aestus Therapeutics, Inc. Méthodes de traitement de la douleur neuroapathique au moyen d'agonistes de ppar-gamma
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
TWI606848B (zh) * 2012-10-08 2017-12-01 Lg生命科學股份有限公司 包含格米列汀與美氟明的組合藥物及其製備方法
CN104788350A (zh) * 2014-01-22 2015-07-22 天津大学 一种通过快速冷却结晶法获得甲糖宁药用优势晶型的方法
CN106831437B (zh) * 2016-02-03 2019-06-21 华中师范大学 含硝基乙烯基的酯类化合物及其制备方法和应用
CN114907285B (zh) * 2021-02-10 2023-09-22 华中师范大学 酰化糖精类化合物及其制备方法和应用、降血糖药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69014562T2 (de) * 1989-01-24 1995-06-22 Gensia Pharma Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.
ES2210728T3 (es) * 1997-03-07 2004-07-01 Metabasis Therapeutics, Inc. Nuevos inhibidores bencimidazol de la fructosa-1, 6-bifosfatasa.
WO1998039344A1 (fr) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Nouveaux composes de purine inhibiteurs de fructose-1,6-biophasphatase
AU6691798A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
EP1070084A4 (fr) * 1998-03-16 2001-09-12 Ontogen Corp Piperazines utilisees en tant qu'inhibiteurs de fructose-1,6-bisphosphatase (fbpase)
DK1112275T3 (da) * 1998-09-09 2003-11-24 Metabasis Therapeutics Inc Hidtil ukendte heteroaromatiske inhibitorer for fructose-1,6-bisphosphatase
NZ512219A (en) * 1998-12-24 2004-12-24 Metabasis Therapeutics Inc A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
ATE346613T1 (de) * 2000-01-21 2006-12-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
GB0015627D0 (en) * 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses

Also Published As

Publication number Publication date
KR20030031952A (ko) 2003-04-23
NO20030034L (no) 2003-03-05
HUP0301830A2 (hu) 2003-11-28
IL153513A0 (en) 2003-07-06
JP2004508297A (ja) 2004-03-18
EP1372660A2 (fr) 2004-01-02
BR0112212A (pt) 2003-12-30
NZ523227A (en) 2005-04-29
ZA200300044B (en) 2004-05-06
AU2001273271B2 (en) 2006-01-05
IL153513A (en) 2014-07-31
KR100854851B1 (ko) 2008-08-27
WO2002003978A2 (fr) 2002-01-17
NO20030034D0 (no) 2003-01-03
HUP0301830A3 (en) 2007-10-29
SK62003A3 (en) 2003-09-11
AU7327101A (en) 2002-01-21
CN100396283C (zh) 2008-06-25
CA2412142A1 (fr) 2002-01-17
WO2002003978A3 (fr) 2003-10-16
CN1599612A (zh) 2005-03-23
MXPA02012713A (es) 2004-09-10
CN101301294A (zh) 2008-11-12
RU2328308C2 (ru) 2008-07-10
CZ20035A3 (cs) 2003-05-14

Similar Documents

Publication Publication Date Title
HUP0302950A3 (en) Synergistic herbicidal composition and a process for its use
AU7327101A (en) A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
IL188471A0 (en) Combinations of dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
GB9900416D0 (en) Inhibitors
IL158195A0 (en) Thiohydantoins and use thereof for treating diabetes
PL373301A1 (en) Phosphodiesterase 4 inhibitors
GB0025782D0 (en) Use of inhibitors
HUP0402506A3 (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
EP1423399A4 (fr) Chelateurs d'hydroxypyridonate et d'hydroxypyrimidinone
GB2361223B (en) Climbing appliance for roping-up and roping-down operations
EP1337255A4 (fr) Utilisation d'inhibiteurs p38 pour le traitement de toux inflammatoire
HK1042695A1 (zh) 蛋白酶抑制劑
HUP0204106A3 (en) Calcilytic compounds and process for their use
AU2001264273A1 (en) Amide compounds and use thereof
AUPQ582400A0 (en) A method of treatment and agents for use therein
GB2389113B (en) B-secretase inhibitor
EP1364653A4 (fr) Inhibiteurs de caspase 3
HUP0302212A3 (en) Fungicidal mixture based on amide compounds and its use
GB0202187D0 (en) "Inhibitors"
HUP0402141A3 (en) Herbicidal composition and process for its use
HUP0500955A3 (en) Cucurbitacin-containing insecticidal composition and a process for its use
AU2002357594A1 (en) Nitrogen-containing heterocyclic compounds and use thereof
GB0021193D0 (en) Inhibitors
GB0029733D0 (en) Inhibitors
GB0015996D0 (en) Inhibitors

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)